VHCP Management II LLC bought a new stake in shares of Kalvista Pharmaceuticals Inc (NASDAQ:KALV) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 759,181 shares of the specialty pharmaceutical company’s stock, valued at approximately $16,785,000. Kalvista Pharmaceuticals accounts for 4.5% of VHCP Management II LLC’s portfolio, making the stock its 8th largest holding. VHCP Management II LLC owned approximately 4.42% of Kalvista Pharmaceuticals as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently bought and sold shares of KALV. Spark Investment Management LLC bought a new position in shares of Kalvista Pharmaceuticals in the 2nd quarter worth approximately $108,000. BlackRock Inc. lifted its stake in shares of Kalvista Pharmaceuticals by 203.8% in the 2nd quarter. BlackRock Inc. now owns 16,205 shares of the specialty pharmaceutical company’s stock worth $132,000 after purchasing an additional 10,871 shares during the period. DRW Securities LLC lifted its stake in shares of Kalvista Pharmaceuticals by 37.3% in the 2nd quarter. DRW Securities LLC now owns 20,600 shares of the specialty pharmaceutical company’s stock worth $167,000 after purchasing an additional 5,600 shares during the period. Virtu Financial LLC bought a new position in shares of Kalvista Pharmaceuticals in the 3rd quarter worth approximately $216,000. Finally, Dimensional Fund Advisors LP bought a new position in shares of Kalvista Pharmaceuticals in the 3rd quarter worth approximately $274,000. Institutional investors and hedge funds own 73.16% of the company’s stock.

NASDAQ KALV traded down $0.91 on Wednesday, reaching $22.85. 89,574 shares of the stock were exchanged, compared to its average volume of 54,054. Kalvista Pharmaceuticals Inc has a one year low of $7.73 and a one year high of $25.57. The stock has a market cap of $413.33 million, a price-to-earnings ratio of -14.93 and a beta of 2.94.

Kalvista Pharmaceuticals (NASDAQ:KALV) last issued its quarterly earnings results on Friday, September 14th. The specialty pharmaceutical company reported ($0.47) EPS for the quarter, missing the consensus estimate of ($0.33) by ($0.14). Kalvista Pharmaceuticals had a negative return on equity of 56.24% and a negative net margin of 132.38%. The business had revenue of $3.72 million for the quarter, compared to the consensus estimate of $4.11 million. Sell-side analysts predict that Kalvista Pharmaceuticals Inc will post -2.07 earnings per share for the current fiscal year.

Several equities analysts have recently weighed in on the stock. BidaskClub cut shares of Kalvista Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, November 7th. Zacks Investment Research upgraded shares of Kalvista Pharmaceuticals from a “hold” rating to a “buy” rating and set a $19.00 target price on the stock in a research note on Wednesday, September 12th. Jefferies Financial Group began coverage on shares of Kalvista Pharmaceuticals in a research note on Tuesday, October 30th. They set a “buy” rating and a $30.00 target price on the stock. Cantor Fitzgerald set a $32.00 target price on shares of Kalvista Pharmaceuticals and gave the stock a “buy” rating in a research note on Monday, November 12th. Finally, Stifel Nicolaus began coverage on shares of Kalvista Pharmaceuticals in a research note on Monday, October 15th. They set a “buy” rating on the stock. One analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $25.25.

In other Kalvista Pharmaceuticals news, Director Albert Cha purchased 1,058,824 shares of the business’s stock in a transaction on Monday, September 10th. The shares were purchased at an average cost of $17.00 per share, with a total value of $18,000,008.00. The purchase was disclosed in a legal filing with the SEC, which is available through this link. Insiders own 38.40% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “VHCP Management II LLC Buys Shares of 759,181 Kalvista Pharmaceuticals Inc (KALV)” was originally posted by Watch List News and is the sole property of of Watch List News. If you are reading this news story on another site, it was illegally copied and reposted in violation of United States and international copyright and trademark laws. The original version of this news story can be viewed at https://www.watchlistnews.com/vhcp-management-ii-llc-buys-shares-of-759181-kalvista-pharmaceuticals-inc-kalv/2662565.html.

Kalvista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors.

Further Reading: Earnings Per Share (EPS) Explained

Institutional Ownership by Quarter for Kalvista Pharmaceuticals (NASDAQ:KALV)

Receive News & Ratings for Kalvista Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kalvista Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.